Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus

Launched by MAYO CLINIC · Aug 2, 2023

Keywords

ClinConnect Summary

This clinical trial is designed to explore how insulin affects the muscles, blood, and overall health in people with Type 1 Diabetes. Researchers aim to learn more about the impact of insulin deprivation (not having enough insulin) and high blood sugar levels on the body. By understanding these effects, the study hopes to improve care for individuals living with this condition.

If you or someone you know has Type 1 Diabetes and is between the ages of 18 and 75, you might be eligible to participate. To join, you would need to be able to give written consent and meet certain health criteria, meaning you shouldn't have severe health issues like heart disease or active kidney problems. Participants will be asked to follow specific guidelines and may undergo tests to help researchers gather important information. This study is not yet recruiting, so it’s a good idea to keep an eye out for when it starts if you’re interested in getting involved.

Gender

ALL

Eligibility criteria

• Inclusion Criteria - Type 1 Diabetes Group:
• • - Able to provide written consent.
• Exclusion Criteria - Type 1 Diabetes Group::
• • BMI \< 20 or \> 32 kg/m\^2.
• • Celiac disease.
• • Pregnancy.
• • Smoking.
• • Reported history of illicit substance use.
• • History of active cardiovascular, cerebrovascular, or peripheral vascular disease.
• • Active renal disease evidenced by estimated glomerular filtration rate (GFR) \< 50 mL/min/1.73 m\^2.
• • Severe peripheral or autonomic neuropathy.
• • Dementia or any other neurologic disease.
• • Uncontrolled psychiatric disease.
• • Any learning disability.
• • Anemia.
• • Thyroid-stimulating hormone (TSH) ≥ 7 or TSH ≤ 7 and free T4 ≤ 0.9.
• • Hemoglobin A1c \> 9.0%.
• • Type 2 Diabetes Mellitus (T2DM), or impaired fasting glucose.
• • Detectable C peptide.
• Inclusion Criteria - Control Group:
• • Able to provide written consent.
• • T1DM treated with continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI) (not Degludec).
• Exclusion Criteria - Control Group:
• • BMI \< 20 or \> 32 kg/m\^2.
• • Celiac disease.
• • Pregnancy.
• • Smoking.
• • Reported history of illicit substance use.
• • History of active cardiovascular, cerebrovascular, or peripheral vascular disease.
• • Active renal disease evidenced by estimated GFR \< 50 mL/min/1.73 m\^2.
• • Severe peripheral or autonomic neuropathy.
• • Dementia or any other neurologic disease.
• • Uncontrolled psychiatric disease.
• • Any learning disability.
• • Anemia.
• • TSH ≥ 7 or TSH ≤ 7 and free T4 ≤ 0.9.
• • T2DM, or impaired fasting glucose.